FINWIRES · TerminalLIVE
FINWIRES

Alterity Therapeutics Secures US FDA Support for ATH434 Phase Three Program

By

-- Alterity Therapeutics (ASX:ATH) said it received positive feedback from a second type C meeting with the US Food and Drug Administration (FDA) on its planned phase three program for drug candidate ATH434, aimed at treating multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.

MSA is a progressive neurodegenerative disorder affecting autonomic and motor function with no approved disease-modifying therapies.

The US FDA provided supportive written feedback on the program's chemistry, manufacturing, and controls, complementing earlier guidance from a separate type C meeting on clinical pharmacology and non-clinical development, the filing added.

Related Articles

International

Ifo: German Export Morale Inches Up in April

German exporters turned slightly optimistic in April, while the overall sector moved neither forward nor backward due to geopolitical uncertainty, the ifo Institute said Monday.The ifo export expectations indicator increased to 0.1 point in April, from -0.7 points in March, as positive expectations roughly offset negative ones.Across the board, the export outlook for the automotive industry, electronics sector, and furniture manufacturers declined but remained generally positive. Expectations for shipments of food and beverages increased "significantly," while energy-intensive businesses forecasted lower exports.

$^SXXP
Mining & Metals

Big Banc Split to Complete Class A Share Split

Big Banc Split (BNK.TO) intends to complete a stock split of its Class A shares, citing strong performance of the shares, the fund said late on Friday.Class A shareholders of record at the close of business on May 1 will receive 20 additional Class A shares for every 100 Class A shares held.At completion of the share split, the Class A shares are expected to begin trading on an ex-split basis at the opening of trading on May 4.The preferred shares of the fund will not be affected and are expected to have downside protection from a decline in the value of the fund's portfolio of about 60%.Class A unitholders will continue to receive regular monthly non-cumulative cash distributions initially in the amount of $0.12 per Class A share, or $1.44 per year, following the Share Split. As a result, the total dollar amount of distributions to be paid to the holders of Class A shares is expected to increase by about 20%.The share split is subject to the approval of the Toronto Stock Exchange.

$BNK.TO
Japan

WTI, Brent Crude Futures Rise Pre-Bell as US, Iran Fail to Engage in Face-to-Face Talks in Pakistan